Experimental Drug Aims to Extend Lifespan of Senior Dogs
Loyal, a veterinary pharmaceutical company, is developing an experimental drug called LOY-002, intended to extend the lifespan of senior dogs by addressing metabolic dysfunction. The drug aims to delay the onset of diseases that reduce the quality of life in older dogs. Currently, Loyal is conducting a final effectiveness study before seeking FDA approval. The FDA has already accepted the drug's Reasonable Expectation of Effectiveness and Target Animal Safety, completing two of the three conditions required for Expanded Conditional Approval. If approved, the drug could be available by 2027. 
